Do omega-3 polyunsaturated fatty acids prevent cardiovascular disease? A review of the randomized clinical trials

Lipid Insights

Volumn 6, Issue , 2013, Pages 13-20

  Kimmig, Lucas M ^a   Karalis, Dean G ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Coronary heart disease; Fish oil; Heart failure; Omega 3 fatty acids

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOCOSAHEXAENOIC ACID; FISH OIL; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; ROSUVASTATIN; TRIACYLGLYCEROL;

ANTIARRHYTHMIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; MEDICAL SOCIETY; META ANALYSIS; META ANALYSIS (TOPIC); PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SUDDEN CARDIAC DEATH; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 84888794886     PISSN: None     EISSN: 11786353     Source Type: Journal    
DOI: 10.4137/LPI.S10846     Document Type: Review

References (29)

1. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-Coast Eskimos. Lancet. 1971;1(7710):1143-6.
2. Leon H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2008;337:a2931.
3. Burr ML, Gilbert JF, Holliday RM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction and reinfarction trial (DART). Lancet. 1989;2(8666):757-61.
4. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-55.
5. Yokoyama M, Origasa H, Matsuzaki M, et al; Japan EPA lipid intervention study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS): a randomized open-label, blinded, end-point analysis. Lancet. 2007;369(9567):1090-8.
6. GISSI-HF Investigators, Tavazzi L, Maggioni R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI- HF trial): a randomized, double-blind, placebo controlled trial. Lancet. 2008;372(9645):1223-30.
7. Karalis DG. In: Van Dijk M, Vitek J, editors. Cardiovascular Health Benefits of Fish Oil. In Fish oil: Production, consumption and health benefits. New York: Nova Science Publishers; 2012:1-32.
8. Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel-versus-aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol. 2009;104(8):1052-4.
9. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids and cardiovascular disease. Circulation. 2002;106(21):2747-57.
10. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2011;123(20):2292-333.
11. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. 2003;57(2):193-200.
12. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015-26.
13. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152-9.
14. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.
15. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-18.
16. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. JAMA. 2012;308(10):1024-33.
17. Macchia A, Levantesi G, Franzosi MG, et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail. 2005;7(5):904-9.
18. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular disease. J Am Coll Cardiol. 2009;54(7):585-94.
19. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Time- course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105(16):1897-903.
20. Saito Y, Yokoyama M, Origasa H, et al; JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200(1):135-40.
21. Kromhout D, Geleijnse JM, de Goede J, et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care. 2011;34(12):2515-20.
22. Vlachopoulos C, Richter D, Stefanadis C. Omega-3 fatty acid supplementation and cardiovascular disease events. JAMA. 2013;309(1):28.
23. Poole CD, Halcox JP, Jenkins-Jones S, et al. Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: A retrospective, matched-cohort study. Clin Ther. 2013;35(1): 40-51.
24. Duda MK, O'Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: Mechanisms and clinical potential. Cardiovasc Res. 2009;84(1):33-41.
25. Xin W, Wei W, Li X. Effects of fish oil supplementation on cardiac function in chronic heart failure: a meta-analysis of randomised controlled trials. Heart. 2012;98(22):1620-5.
26. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33(1): 159-71.
27. ASCEND: A Study of Cardiovascular Events iN Diabetes. Available at: http://www.clinicaltrials.gov/show/NCCT00135226. Accessed Jan 21, 2013.
28. REDUCE-IT: A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on a statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event. Available at: http://www.clinicaltrials.gov/show/NCT00056407. Accessed Jan 21, 2013.
29. SUPERIORSVG: Improving the results of heart bypass surgery using new approaches to surgery and medication. Available at: http://www.clinicaltrials.gov/show/NCT01047449. Accessed Jan 21, 2013.